Login to Your Account

Financings Roundup

Tuesday, April 9, 2013
• Canbex Therapeutics Ltd., of London, said it completed £2.1 million (US$3.2 million) fundraising round that will enable the firm to complete the early development of its lead compound for treating spasticity in multiple sclerosis.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription